preservative-free parenteral treprostinil — Competitive Intelligence Brief

preservative-free parenteral treprostinil (preservative-free parenteral treprostinil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostacyclin analog. Area: Cardiovascular.

phase 3 Prostacyclin analog Prostacyclin receptor (IP receptor) Cardiovascular Small molecule

Target snapshot

preservative-free parenteral treprostinil (preservative-free parenteral treprostinil) — AOP Orphan Pharmaceuticals AG. Treprostinil mimics the action of prostacyclin, which is a natural substance that dilates blood vessels and prevents platelet aggregation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
preservative-free parenteral treprostinil TARGET	preservative-free parenteral treprostinil	AOP Orphan Pharmaceuticals AG	phase 3	Prostacyclin analog	Prostacyclin receptor (IP receptor)
Inhaled Epoprostenol and phenylephrine	Inhaled Epoprostenol and phenylephrine	University Health Network, Toronto	marketed	Prostacyclin analog with alpha-1 adrenergic agonist	Prostacyclin receptor (IP receptor); alpha-1 adrenergic receptor
FLOLAN injection with reformulated diluent	FLOLAN injection with reformulated diluent	GlaxoSmithKline	marketed	Prostacyclin analog	Prostacyclin receptor (IP receptor)
Epalrestat,Mecobalamin	Epalrestat,Mecobalamin	Xiangya Hospital of Central South University	marketed	Prostacyclin analog + Cobalamin derivative combination	Prostacyclin receptor (IP receptor) + Methylcobalamin-dependent enzymes
iloprost nebuliser solution	iloprost nebuliser solution	Shanghai Jiao Tong University School of Medicine	phase 3	Prostacyclin analogue	Prostacyclin receptor
Iloprost Injection, for intravenous use	Iloprost Injection, for intravenous use	Civi Biopharma, Inc.	phase 3	Prostacyclin analog	Prostacyclin receptor (IP receptor)
LIQ861 Inhaled Treprostinil	LIQ861 Inhaled Treprostinil	Liquidia Technologies, Inc.	phase 3	Prostacyclin analog	Prostacyclin receptor (IP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostacyclin analog class)

1. Liquidia Technologies, Inc. · 2 drugs in this class
2. AOP Orphan Pharmaceuticals AG · 1 drug in this class
3. Civi Biopharma, Inc. · 1 drug in this class
4. GlaxoSmithKline · 1 drug in this class
5. Ludwig-Maximilians - University of Munich · 1 drug in this class
6. Lung Biotechnology PBC · 1 drug in this class